|

ACI-24.060 at Dose C Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • AC Immune SA1

Indications

  • Prodromal Alzheimer's Disease1
  • DSAD1
  • Beta-Amyloid1
  • Amyloid Plaque1
  • Alzheimer's Disease1

Phoenix, Arizona1 trial

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Barrow Neurological Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.